Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Financial Flexibility Index
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Financial Flexibility Index of 0.35x as of December 2025. Free cash flow of CN¥307.91 Million (operating CF CN¥287.81 Million minus capex CN¥20.11 Million) represents 0% of total liabilities (CN¥890.89 Million). Check Tianjin Lisheng Pharmaceutical Co Ltd (002393) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Tianjin Lisheng Pharmaceutical Co Ltd Financial Flexibility Index (2007–2025)
Historical Financial Flexibility Index trend for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. For the full cash flow conversion analysis, see 002393 cash generation efficiency.
Annual Financial Flexibility Index for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year free cash flow to debt coverage for Tianjin Lisheng Pharmaceutical Co Ltd. Explore Tianjin Lisheng Pharmaceutical Co Ltd (002393) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.55x | CN¥489.31 Million | CN¥451.85 Million | CN¥890.89 Million | ▲ +281.2% |
| 2024 | 0.14x | CN¥142.01 Million | CN¥88.26 Million | CN¥985.54 Million | ▼ -53.4% |
| 2023 | 0.31x | CN¥271.23 Million | CN¥209.51 Million | CN¥877.17 Million | ▼ -21.8% |
| 2022 | 0.40x | CN¥372.30 Million | CN¥331.38 Million | CN¥941.66 Million | ▲ +8.4% |
| 2021 | 0.36x | CN¥284.58 Million | CN¥196.34 Million | CN¥780.42 Million | ▲ +48.3% |
| 2020 | 0.25x | CN¥177.03 Million | CN¥76.37 Million | CN¥720.09 Million | ▼ -41.4% |
| 2019 | 0.42x | CN¥358.78 Million | CN¥268.33 Million | CN¥855.85 Million | ▲ +10.6% |
| 2018 | 0.38x | CN¥267.12 Million | CN¥162.69 Million | CN¥704.85 Million | ▼ -0.5% |
| 2017 | 0.38x | CN¥229.34 Million | CN¥179.25 Million | CN¥602.32 Million | ▼ -42.3% |
| 2016 | 0.66x | CN¥310.80 Million | CN¥173.60 Million | CN¥470.60 Million | ▼ -27.9% |
| 2015 | 0.92x | CN¥402.73 Million | CN¥198.13 Million | CN¥439.50 Million | ▼ -14.7% |
| 2014 | 1.07x | CN¥362.89 Million | CN¥72.24 Million | CN¥337.89 Million | ▼ -46.9% |
| 2013 | 2.02x | CN¥602.72 Million | CN¥289.62 Million | CN¥298.20 Million | ▼ -37.0% |
| 2012 | 3.21x | CN¥475.07 Million | CN¥250.72 Million | CN¥148.13 Million | ▼ -31.6% |
| 2011 | 4.69x | CN¥300.53 Million | CN¥134.58 Million | CN¥64.07 Million | ▲ +41.2% |
| 2010 | 3.32x | CN¥256.24 Million | CN¥186.55 Million | CN¥77.12 Million | ▲ +539.3% |
| 2009 | 0.52x | CN¥213.74 Million | CN¥196.14 Million | CN¥411.26 Million | ▼ -26.5% |
| 2008 | 0.71x | CN¥191.45 Million | CN¥126.59 Million | CN¥270.58 Million | ▲ +65.5% |
| 2007 | 0.43x | CN¥188.86 Million | CN¥174.94 Million | CN¥441.87 Million | — |